Just normal life in this crazy grey market communityIn this episode, I look at another ridiculous corner of the grey market community, where public kit photos can suddenly become a copyright issue, and a petty trademark attempt over the name K-Hole somehow becomes part of the drama.

From the JEEP T30 fallout to a completely separate attempt to claim ownership over my server name, K -Hole, this one is less about peptides and more about control, assumptions, and grey market nonsense.

Same madness. Nothing dull here.

A practical guide to navigating vendors, risk, and uncertainty for those new to this worldThis guide is for anyone trying to crack the grey market for the first time. It’s what I would do if I were starting out now, knowing everything I know today.

This episode covers the basics: what to do after joining my servers, how to start reading the market, and how to find a vendor for your very first order.

I cover how vendors operate, how to spot red flags in live chats, why a COA is only one piece of the puzzle, and why your first purchase should be treated as a trial run, not a lifetime commitment.

There are no shortcuts. You need to be prepared to make some effort, spend some time, and learn how this world actually works before you send money.

It's a practical look at how not to get caught out on your first move.

Happy Shopping

This episode breaks down what GMP and cGMP actually mean, and why broad cGMP claims on RUO peptide websites should be treated with scepticism.

GMP and cGMP are strict quality systems overseen by regulators such as the FDA. They require traceability, documented processes, controlled environments, QA oversight, and inspection. If those controls are missing, the GMP claim falls apart.

A major grey-market tactic is confusing API GMP with finished-product GMP. An API certificate may say something about the raw peptide powder, but it does not prove anything about the final vial: filling, lyophilisation, sterility, storage, or batch release.

The contradiction becomes sharper when products are labelled Research Use Only while also being marketed as cGMP compliant. RUO products sit outside the drug regulatory framework, while cGMP implies regulated manufacturing controls.

A legitimate US cGMP claim should be traceable. At minimum, buyers should be able to ask for the facility name, FEI number, registration status, inspection history, and the scope of what is actually GMP-compliant.

Without that, “cGMP compliant” is not evidence. It’s marketing.

How “seized shipments” turn into second profits and why the same buyers may pay twiceScams are nothing new in the grey market.

But this one works a little differently.

In this episode, we break down what’s being described as the “Phoenix group buy scam” a pattern where a failed or allegedly failed group buy may not be the end of the story.

Instead, it can become the starting point for something else.

We walk through how these setups typically unfold:

how trust is built inside the communityhow buyers are funnelled into group buyshow delays and shortages are normalisedand how the narrative is already in place before anything goes wrongUsing the Opaline Health & Science case as a real example, Part 1 focuses on the structure, not the outcome.

Because the key question isn’t just what happened.

It’s how the system was built to begin with.

This episode explores a side of the grey zone that isn’t talked about enough.

Not the peptides. Not the vendors. Not the scams.

But the people.

Inside tight-knit communities, friendship often comes with conditions. You’re valuable while you’re useful. But when that changes, so does the relationship.

From gossip, alt accounts, back stabbing and surveillance… to something more personal, the emotional whiplash of people who feel real, disappear, and then return like nothing happened.

This episode is a reflection on hypocrisy, status, loyalty and the shifting terms of friendship in the grey zone

Scams, impersonators, vendor disputes, disappearing chats, and a collaboration offer I definitely wasn’t expecting.

This episode is a real-time look at what one day in the grey zone actually looks like for me, narrated in my own voice.

What really happens when tirzepatide and vitamin B12 are mixed in the same vial?

In this deep dive, we break down the science behind Eli Lilly’s recent warning and preprint, which identified a previously unknown tirzepatide–B12 molecular complex in compounded samples, in some cases making up a significant portion of the vial. The analysis also revealed major potency variation, with some products testing far below their labelled strength.

But the real question isn’t just what was found, it’s what it actually means.

We explore:

how and why molecules interact differently in a shared vial vs the human body

what Lilly’s analytical data proves, and what it doesn’t

why formulation conditions (pH, concentration, solvent) can drive structural change

and how theoretical risks like aggregation and immunogenicity should be interpreted

This episode separates chemical possibility from clinical reality, and explains why understanding where interactions occur is key to understanding whether they matter at all.

What their data shows and what it still doesn't explain.

What happens when a blockbuster drug meets a common vitamin?

In this deep dive, we unpack Eli Lilly’s warning about tirzepatide mixed with vitamin B12, and the science behind the controversy.

A newly released preprint shows that when the two are combined, they can form a previously unknown molecular complex, detected in real world samples. Some products were also found to be significantly under strength, raising broader concerns about quality in the secondary market.

But while the chemistry is real, the key question remains unanswered:

does any of this actually matter for patients?

We break down:

what Lilly’s data actually proves

how the molecules interact at a structural level

why lab findings don’t automatically translate to real-world risk

and how this fits into the wider $100B GLP-1 market battle

This isn’t just a story about one drug or one impurity, it’s about the gap between analytical evidence and clinical reality, and what happens when patients are caught in the middle.

Why do some labs report 99%+ purity for NAD, while others refuse to give a purity number at all?

This episode unpacks what is known as the NAD Testing Paradox.

NAD is often analysed using methods designed for peptides, but chemically it behaves very differently. Because NAD naturally breaks down into related molecules like nicotinamide, ADP-ribose, AMP and ADP, purity numbers can sometimes reflect the analytical method used, rather than the actual chemical state of the molecule.

Using real COA examples, this episode explores;

why peptide style testing can be misleading for NAD

how different labs can end up reporting very different numbers

cases where laboratories even disagreed on the identity of a sample

what a properly selective NAD testing method actually looks like

The goal isn’t to criticise labs, but to explain why NAD purity numbers can appear contradictory, and what those results may actually be measuring.

How Telehealth, US Manufacturing and 503A Ambitions are Rebuilding the Peptide Market

The peptide market may be moving into a new phase.

For years, much of the industry operated through Research Use Only (RUO) websites selling peptides in a legal grey zone. But that model is coming under pressure from payment processors, regulators, and changing mrket expectations.

This episode explores what may be replacing it.

Rather than a simple shift from RUO vendors to legitimate pharmacies, a more complex infrastructure appears to be emerging: telehealth platforms, physician sign-off models, compounding pharmacies, and even underground U.S. manufacturing operations trying to move toward 503A licensing over time.

We break down how clinics created demand for alternative peptide supply, why telehealth has become such an attractive distribution layer, what legitimate sterile compounding actually involves, and why some operators may be using telehealth as a bridge toward a more defensible healthcare structure.

The key point is that this is not a clean transition from grey market to regulated pharmacy.

It is a hybrid phase in which:

some operations are fully licensed pharmacies

some are Telehealth driven prescribing systems

some are clinic facing vendor networks wrapped in physician sign-off

and some may be underground U.S. manufacturers trying to acquire the telehealth layer now and the 503A wrapper later

Demand for peptides hasn’t disappeared.

What’s changing is the infrastructure through which that demand is served, and who manages to control the next version of the market.